SEC Form 4/A · accession 0001567619-19-001608

KalVista Pharmaceuticals, Inc. · KALV

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.

Reporting owner

Officer — Chief Development Officer

Period of report

Nov 21, 2016

Accepted (ET)

Jan 24, 2019 · 7:44 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001348911

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F1,F2,F3,F4	$0.0043	Nov 21, 2016	A	116,810	A	—	Mar 30, 2026	Common Stock	116,810	116,810	D

F1Common Stock was received in exchange for 285,000 shares of KalVista Pharmaceuticals, Ltd. ordinary shares in connection with the closing of the share purchase transaction (the "Transaction") whereby KalVista Pharmaceuticals, Ltd. became a wholly-owned subsidiary of Carbylan Therapeutics, Inc., which changed its name to KalVista Pharmaceuticals, Inc. (the "Company"). On the effective date of the Transaction, the closing price of the Company's common stock was $9.38 per share. All numbers give effect to the 14:1 reverse stock split effected by the Company on November 21, 2016 (the "Reverse Stock Split"). Prior to the reverse stock split, the closing price of the Company's common stock was $0.67 per share.
F2The stock option was received in exchange for 401,250 shares of KalVista Pharmaceuticals, Ltd. ordinary shares in connection with the closing of the Transaction. The option became 100% vested as of May 1, 2016. All numbers give effect to the Reverse Stock Split.
F3This amended Form 4 is being filed solely to correct the exercise price for the employee stock option.
F4The option became 100% vested and exercisable as of May 1, 2016.